Angiogenesis, metastasis, and lung cancer. An overview.

[1]  K. O'Byrne,et al.  A biological staging model for operable non-small cell lung cancer , 2001, Thorax.

[2]  D. Hicklin,et al.  Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. , 2001, Cancer research.

[3]  S. Fan,et al.  Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Ellis,et al.  The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. , 2001, Cancer research.

[5]  N. Aoike,et al.  Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. , 2001, The Journal of allergy and clinical immunology.

[6]  G. Taraboletti,et al.  Preclinical development of metalloproteasis inhibitors in cancer therapy. , 2001, Critical reviews in oncology/hematology.

[7]  W. Arap,et al.  Vascular targeting and antigen presentation , 2001, Nature Immunology.

[8]  R K Jain,et al.  Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Ellis,et al.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. , 2000, The American journal of pathology.

[10]  L. Liotta,et al.  Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  L. Ellis,et al.  Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. , 2000, The American journal of pathology.

[12]  A. Yuan,et al.  Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. , 2000, American journal of respiratory and critical care medicine.

[13]  M. Dewhirst,et al.  Review of methods used to study oxygen transport at the microcirculatory level , 2000, International journal of cancer.

[14]  A. Harris,et al.  ‘Invading edge vs. inner’ (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non‐small cell lung cancer , 2000, The Journal of pathology.

[15]  J. Minna,et al.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.

[16]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[17]  L. Ellis,et al.  Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases , 2000, Cancer.

[18]  M. Burdick,et al.  CXC chemokines in angiogenesis , 2000, Journal of leukocyte biology.

[19]  C. Bucana,et al.  Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  R. Crystal,et al.  Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. , 2000, American journal of respiratory cell and molecular biology.

[21]  I. Fidler,et al.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. , 2000, Cancer research.

[22]  J. Mendelsohn,et al.  Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c- jun N-terminal kinase activity , 2000, British Journal of Cancer.

[23]  L. Ellis,et al.  Critical determinants of neoplastic angiogenesis. , 2000, Cancer journal.

[24]  I. Fidler.  Angiogenesis and cancer metastasis. , 2000, Cancer journal.

[25]  S. Carter,et al.  Clinical strategy for the development of angiogenesis inhibitors. , 2000, The oncologist.

[26]  E. Smit,et al.  Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. , 2000, The oncologist.

[27]  David Warburton,et al.  The molecular basis of lung morphogenesis , 2000, Mechanisms of Development.

[28]  C. Bucana,et al.  Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  C. Bucana,et al.  Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[31]  M. Ghazizadeh,et al.  Mosaic‐like distribution of endothelial cell antigens in capillaries and juxta‐alveolar microvessels in the normal human lung , 2000, Pathology international.

[32]  S. Rafii,et al.  Circulating endothelial precursors: mystery, reality, and promise. , 2000, The Journal of clinical investigation.

[33]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[34]  M. Volm,et al.  PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. , 1999, Anticancer research.

[35]  L. Ellis,et al.  Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  C. Bucana,et al.  Regulation of distinct steps of angiogenesis by different angiogenic molecules. , 1998, International journal of oncology.

[37]  C. Bucana,et al.  Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence , 1998 .

[38]  C. Angeletti,et al.  Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.

[39]  C. Angeletti,et al.  Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. , 1997, British Journal of Cancer.

[40]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[41]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[42]  L. Ellis,et al.  Multiparametric in situ messenger RNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinomas. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  C. Bucana,et al.  Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. D'Amato,et al.  Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.

[45]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[46]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[47]  C. Bucana,et al.  Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. , 1994, Cancer research.

[48]  R. Auerbach,et al.  Angiogenesis inhibition: a review. , 1994, Pharmacology & therapeutics.

[49]  M. Bhargava,et al.  The interaction of HGF-SF with other cytokines in tumor invasion and angiogenesis. , 1993, EXS.

[50]  J. Azizkhan,et al.  In vitro model of angiogenesis using a human endothelium‐derived permanent cell line: Contributions of induced gene expression, G‐proteins, and integrins , 1992, Journal of cellular physiology.

[51]  J. Mulliken,et al.  Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy , 1992, The New England journal of medicine.

[52]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[53]  J. Mendelsohn.  The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. , 1990, Seminars in cancer biology.

[54]  L. Liotta,et al.  Metalloproteinases and cancer invasion. , 1990, Seminars in cancer biology.

[55]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[56]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[57]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[58]  E. Goldmann.  The Growth of Malignant Disease in Man and the Lower Animals, with special reference to the Vascular System. , 1907, Proceedings of the Royal Society of Medicine.